Nothing Special   »   [go: up one dir, main page]

US3535422A - Stable benzoyl peroxide composition - Google Patents

Stable benzoyl peroxide composition Download PDF

Info

Publication number
US3535422A
US3535422A US711861A US3535422DA US3535422A US 3535422 A US3535422 A US 3535422A US 711861 A US711861 A US 711861A US 3535422D A US3535422D A US 3535422DA US 3535422 A US3535422 A US 3535422A
Authority
US
United States
Prior art keywords
benzoyl peroxide
composition
water
weight
sulfur
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US711861A
Inventor
Richard M Cox
Leonard R Ciufo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Research Australia Pty Ltd
Stiefel Laboratories Inc
Original Assignee
Stiefel Research Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Research Australia Pty Ltd filed Critical Stiefel Research Australia Pty Ltd
Application granted granted Critical
Publication of US3535422A publication Critical patent/US3535422A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38Percompounds, e.g. peracids

Definitions

  • a therapeutic composition for the treatment of acne comprising a uniform dispersion of benzoyl peroxide in a fluid medium containing water and at least one organic emollient is disclosed.
  • the composition contains from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25 by weight of the organic emollients and from about 50 to 90% by weight water.
  • the organic emollient constituents of the composition are saturated organic compounds that are inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, whereby the composition is stable in storage without the addition of a stabilizer thereto.
  • Acne and seborrhea are conditions of the human skin characterized by an excessive flow of sebum, or skin oil, from the sebaceous glands which are located in the pilosebaceous apparatus.
  • the channel through which sebum reaches the skin surface is the duct of the hair follicle.
  • the presence of excessive amounts of sebum in the duct and on the skin acts to block or stagnate the continuous flow of sebum from the follicular duct, thus producing a thickening of the sebum which becomes a solid plug known as a comedone.
  • hyperkeratinization of the follicular opening is stimulated, thus completely closing the duct.
  • the usual result is a papule, a pustule, or a cyst, often contaminated with bacteria which cause secondary infections.
  • ком ⁇ онентs are employed in the treatment of acne and seborrhea to prevent the blocking of the follicular duct, to reopen the duct once it has become blocked, to act against the infecting bacteria or the thickened sebum, or to provide combinations of each of these actions.
  • the horny outer layer of the skin is formed of dead cells composed largely of a substance known as keratin, and therapeutic agents which act to prevent the blocking of the follicular duct by promoting the removal or sluffing off of excess keratin are known as keratolytic agents.
  • benzoyl peroxide is substantially insoluble in water, and it is ordinarily incorporated in conventional ointments and creams containing water and other common organic and inorganic constituents by first dissolving the peroxide in a volatile organic solvent such as chloroform which is then mixed with the other aqueous and nonaqueous ingredients of the composition. The resulting mixture is then permitted to stand or age for several days in order to allow the organic solvent to evaporate from the composition before it is applied to the skin.
  • a volatile organic solvent such as chloroform
  • compositions containing benzoyl peroxide, Water and other common organic and mineral components of such preparations display a gradual loss of potency, and that after about four months the level of benzoyl peroxide remaining in the composition is below that necessary to produce the desired therapeutic eiiects.
  • Any attempt to stabilize the composition by adding antioxidants thereto inhibits the acitivity of the benzoyl peroxide and defeats the purpose of the composition. Consequently, it is the usual practice when preparing therapeutic compositions containing benzoyl peroxide to supply the user with separate packages of benzoyl peroxide and a base formulation which are mixed together just prior to using the composition.
  • compositions containing water, organic emollients and therapeutically effective benzoyl peroxide can be prepared which are stable over a period of time at least equal to the normal commercial life of ordinary pharmaceutical preparations. Moreover, these new compositions display full stability with respect to the benzoyl peroxide component thereof even when subjected to temperatures higher than those normally expected in the ordinary use of the product.
  • the stability of our new benzoyl peroxide-containing composition is predicated on our discovery that if the base or fluid medium in which the benzoyl peroxide is dispersed contains only water and organic emollients which are substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and which have a boiling point higher than water, the benzoyl peroxide constituent thereof will not be decomposed nor react with the base, and therefore will be able to exert its full therapeutic activity as an oxidizing and kerotolytic agent when applied topically to the skin of a patient.
  • the composition of our invention comprises a dispersion of finely divided particles of benzoyl peroxide in a water-containing fluid medium that is substantially free of dissolved benzoyl peroxide, the composition containing from about 1 to 25% by weight of benzoyl peroxide, from about 2 to 25% by weight of at least one organic emollient that is substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and from about 50 to 90% by weight water.
  • composition of our invention must contain sufiicient benzoyl peroxide to be therapeutically effective, and should not contain more peroxide than can be uniformly dispersed in the fluid base to form a smoothly spreadable cream or ointment.
  • these considerations dictate that the composition contain at least about 1% and not more than about 25% by weight benzoyl peroxide, and we presently prefer that the composition contain from about 5 to about by weight benzoyl peroxide.
  • the benzoyl peroxide constituent of the composition should be of high purity (that is, in the order of 98:1% (C H CO) O and in the form of relatively finely divided crystalline particles.
  • the composition also contains from about 2 to by weight of at least one, and usually several, of certain organic emollients.
  • the organic emollient constituents of the composition should be selected from among those which are inert, and which are substantially non-ionic and non-polar, with respect to benzoyl peroxide and the other ingredients of the composition, and further from among those which have a boiling point higher than water.
  • inert refers to organic emollients which do not react chemically with benzoyl peroxide or with the other constituents of the composition at ambient temperature and pressure. In this connection, we have found that the presence of unsaturated carbon atoms in the emollient has an adverse effect on the stability and shelf life of the composition.
  • the emollients preferably should be saturated organic compounds; that is, organic compounds that have no double or triple carbon to carbon atom bonds in the hydrocarbon chain.
  • the terms non-ionic and non-polar as employed herein refer to emollient organic compounds which are insoluble in water at ordinary temperatures, or if soluble in water do not ionize therein to an appreciable degree.
  • the requirement that the emollients have a boiling point higher than water is of importance to insure that some of the emollient will remain on the skin of the patient as a vehicle for the benzoyl peroxide after the evaporation of the Water content of the composition therefrom.
  • Emollient compounds meeting these criteria include, but are not limited to, aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, fatty acids having from 12 to 20 carbon atoms, and the esters of said acids.
  • organic compounds representative of those useful in compositions of our invention include, but are not limited to, butyl alcohol, isobutyl alcohol, amyl alcohol, iso-amyl alcohol, hexyl alcohol, isohexyl alcohol, and the essentially water-insoluble higher aliphatic alcohols which are soluble in or softened by the aforementioned alcohols; ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol and the like; lauric acid, myristic acid, palmitic acid, stearic acid, and the like; and ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, isopropyl myristate, ethyl palmitate, isopropyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stea
  • the composition contains from about 50 to by weight water in which benzoyl peroxide is substantially insoluble.
  • it also contains emulsifiers for the aqueous and non-aqueous phases of the composition, for example, polyethylene glycol 1000 monostearate, as well as preservatives such as methyl paraben (the methyl ester of parahydroxybenzoic acid) to prevent mold growth.
  • the composition also advantageously contains from about 1 to 25% by weight of finely divided sulfur, and preferably from about 2 to 10% by weight of precipitated sulfur, U.S.P. grade.
  • Sulfur is an antimicrobial and keratolytic agent that has long been used in the treatment of acne. Although it is not known precisely how sulfur exerts its keratolytic effect on the skin, it is through that hydrogen sulfide, which is formed when sulfur is in contact with animal tissue, reacts with alkali in tissue fluids to produce active sulfides which, in turn, promote keratolysis. The combination of precipitated sulfur with benzoyl peroxide produces significantly greater keratolysis than either substance will when used alone. The mechanism responsible for this result is not known.
  • benzoyl peroxide facilitates the reaction between the active sulfides and keratin, or benzoyl peroxide may have some direct effect or keratin which makes it more susceptible to the action of the sulfide.
  • benzoyl peroxide and sulfur in our new composition gives the composition properties which are especially useful in the treatment of acne.
  • the composition is prepared by carefully and thoroughtly blending the benzoyl peroxide, organic emollient, water and other constituents of the composition.
  • the fluid medium in which the benzoyl peroxide is to be dispersed is first prepared by forming an emulsion of the aqueous and non-aqueous phases of the fluid medium.
  • the benzoyl peroxide and sulfur, if any, constituents of the composition are then added to the emulsion and thoroughly blended therewith to form the therapeutic compostion of our invention.
  • the benzoyl peroxide constituent is in the form of dry, finely divided crystalline particles no further treatment of the composition is required, however, When the benzoyl peroxide is in the form of relatively coarse crystals packaged wet With water, the mixture of benzoyl peroxide and water is thoroughly mixed with a previously emulsified mixture of the emollient and water constituents of the composition, and the composition is then milled to physically reduce the particle size of the benzoyl peroxide crystals so that substantially all of the particles are smaller than 0.25 mm. in size.
  • composition is applied topically to the skin of the patient by rubbing the cream or ointment in well,
  • composition of our invention contains 5% benzoyl peroxide and 2% sulfur.
  • compositions containing 20% benzoyl peroxide and up to 25% sulfur have been used by individuals with dark, very oily skin and by those who have developed resistance to compositions of lesser strength, and compositions containing only 1.25% benzoyl peroxide and 0.5% sulfur have been used by individuals with fair and delicate skin.
  • the compositions prepared in accordance with our invention are stable and retain full potency of the benzoyl peroxide constituent thereof for a period of time, i.e., for about eight years or more, which far exceeds the normal requirements for a pharmaceutical product.
  • a therapeutic composition for the treatment of acne that is stable in storage Without the addition of a stabilizer thereto which consists of a uniform dispersion of finely divided particles of crystalline benzoyl peroxide in a fluid medium consisting essentially of water and an organic emollient selected from the group consisting of saturated aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, saturated fatty acids having from 12 to 20 carbon atoms, lower alkyl and glyceryl esters of said fatty acids having from 12 to 20 carbon atoms, and mixtures thereof, said organic emollient being inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, said composition containing from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25% by weight of said organic emollient and from about 50 to 90% by weight water.
  • an organic emollient selected from the group consisting of saturated alipha
  • composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide.
  • composition according to claim 1 in which the composition contains from about 1 to 25% by weight finely divided sulfur.
  • composition contains from about 5 to 10% by weight benzoyl peroxide and from about 2 to 10% by weight finely divided sulfur.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Birds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

United States Patent O US. Cl. 424--164 4 Claims ABSTRACT OF THE DISCLOSURE A therapeutic composition for the treatment of acne comprising a uniform dispersion of benzoyl peroxide in a fluid medium containing water and at least one organic emollient is disclosed. The composition contains from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25 by weight of the organic emollients and from about 50 to 90% by weight water. The organic emollient constituents of the composition are saturated organic compounds that are inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, whereby the composition is stable in storage without the addition of a stabilizer thereto.
BACKGROUND OF THE INVENTION This is a continuationin-part of our co-pending United States patent application Ser. No. 538,567, filed Mar. 30, 1966, now abandoned, entitled Therapeutic Composition.
Acne and seborrhea are conditions of the human skin characterized by an excessive flow of sebum, or skin oil, from the sebaceous glands which are located in the pilosebaceous apparatus. The channel through which sebum reaches the skin surface is the duct of the hair follicle. The presence of excessive amounts of sebum in the duct and on the skin acts to block or stagnate the continuous flow of sebum from the follicular duct, thus producing a thickening of the sebum which becomes a solid plug known as a comedone. When this occurs, hyperkeratinization of the follicular opening is stimulated, thus completely closing the duct. The usual result is a papule, a pustule, or a cyst, often contaminated with bacteria which cause secondary infections. These occurrences characterize the disease state known as acne, and in lesser severity, seborrhea.
Many topical therapeutic agents are employed in the treatment of acne and seborrhea to prevent the blocking of the follicular duct, to reopen the duct once it has become blocked, to act against the infecting bacteria or the thickened sebum, or to provide combinations of each of these actions. The horny outer layer of the skin is formed of dead cells composed largely of a substance known as keratin, and therapeutic agents which act to prevent the blocking of the follicular duct by promoting the removal or sluffing off of excess keratin are known as keratolytic agents. For example, the use of sulfur as a mild cutaneous irritant to remove the horny layer of skin, and with the the debris clogging the follicular openings, is Well known in the art, and other substances such as resorcinol and salicylic acid have also long been used as keratolytic agents in the treatment of acne. It has recently been proposed that benzoyl peroxide, which is a powerful oxidizing agent, be employed as an antibacterial and keratolytic agent in the treatment of acne, and an extensive clinical evaluation of this substance has conclusively demonstrated its eflectiveness for this purpose when employed by itself or, particularly, when employed in conjunction with finely divided sulfur.
ice
Benzoyl peroxide, (C H CO) O is a colorless, odorless, tasteless, crystalline solid that is stable at ordinary room temperatures but which is flammable and is capable of exploding when confined and subjected to grinding heat or flame. It is a powerful oxidizing agent completely non-toxic to man, and because of its lack of local injurious or irritating effects and its lack of penetration into tissue with consequent protein precipitation it has been used topically for its antiseptic and healing properties for many years. More recently, it has been used as a very effective keratolytic and antibacterial agent in the treatment of acne. The material is advantageously incorporated in a cream or ointment base for convenience in applying it to the skin. However, benzoyl peroxide is substantially insoluble in water, and it is ordinarily incorporated in conventional ointments and creams containing water and other common organic and inorganic constituents by first dissolving the peroxide in a volatile organic solvent such as chloroform which is then mixed with the other aqueous and nonaqueous ingredients of the composition. The resulting mixture is then permitted to stand or age for several days in order to allow the organic solvent to evaporate from the composition before it is applied to the skin. However, it has been found that when benzoyl peroxidecontaining compositions prepared in the manner described are kept at a room temperature for a few days, bubbles of gas evolve indicating that some reaction is taking place between the benzoyl peroxide and the base. Experience has shown that most compositions containing benzoyl peroxide, Water and other common organic and mineral components of such preparations display a gradual loss of potency, and that after about four months the level of benzoyl peroxide remaining in the composition is below that necessary to produce the desired therapeutic eiiects. Any attempt to stabilize the composition by adding antioxidants thereto inhibits the acitivity of the benzoyl peroxide and defeats the purpose of the composition. Consequently, it is the usual practice when preparing therapeutic compositions containing benzoyl peroxide to supply the user with separate packages of benzoyl peroxide and a base formulation which are mixed together just prior to using the composition.
SUMMARY OF THE INVENTION We have now discovered that compositions containing water, organic emollients and therapeutically effective benzoyl peroxide can be prepared which are stable over a period of time at least equal to the normal commercial life of ordinary pharmaceutical preparations. Moreover, these new compositions display full stability with respect to the benzoyl peroxide component thereof even when subjected to temperatures higher than those normally expected in the ordinary use of the product. The stability of our new benzoyl peroxide-containing composition is predicated on our discovery that if the base or fluid medium in which the benzoyl peroxide is dispersed contains only water and organic emollients which are substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and which have a boiling point higher than water, the benzoyl peroxide constituent thereof will not be decomposed nor react with the base, and therefore will be able to exert its full therapeutic activity as an oxidizing and kerotolytic agent when applied topically to the skin of a patient. The relative proportions of benzoyl peroxide, water and organic emollients present in the compositions are important only insofar as the composition is therapeutically effective and cosmetically acceptable. Accordingly, the composition of our invention comprises a dispersion of finely divided particles of benzoyl peroxide in a water-containing fluid medium that is substantially free of dissolved benzoyl peroxide, the composition containing from about 1 to 25% by weight of benzoyl peroxide, from about 2 to 25% by weight of at least one organic emollient that is substantially inert, non-polar and non-ionic with respect to the other constituents of the composition and from about 50 to 90% by weight water. The composition also advantageously contains from about 1 to 25 by weight finely divided sulfur, as well as emulsifiers for the aqueous and non-aqueous phases of the fluid medium, antibacterial agents, mold growth inhibitors, and the like. Compositions prepared in accordance with our invention possess a stability which far exceeds the normal requirements for a pharmaceutical product, based upon its normally expected commercial life. For example, when our new compositions are stored at 40 C., 100% of the benzoyl peroxide can be recovered at the end of 12 months. This approximates a normal shelf life of eight years.
DETAILED DESCRIPTION The composition of our invention must contain sufiicient benzoyl peroxide to be therapeutically effective, and should not contain more peroxide than can be uniformly dispersed in the fluid base to form a smoothly spreadable cream or ointment. These considerations dictate that the composition contain at least about 1% and not more than about 25% by weight benzoyl peroxide, and we presently prefer that the composition contain from about 5 to about by weight benzoyl peroxide. The benzoyl peroxide constituent of the composition should be of high purity (that is, in the order of 98:1% (C H CO) O and in the form of relatively finely divided crystalline particles. High purity benzoyl peroxide in the form of dry crystals having a particle size such that at least 99% will pass thru a 60 mesh screen (Tyler Standard) is available commercially, and this form of the peroxide can be blended directly with the other constituents of the composition, without further reduction in the particle size of the peroxide crystals, to form a finished product. However, we presently prefer to employ a somewhat more coarsely crystalline form of benzoyl peroxide that is packaged wet with Water, a fact which greatly increases the safety with which the peroxide can be handled. The wet packed peroxide is dustless, free flowing and disperses readily in the fluid medium comprising the balance of our new composition. The various ingredients of the composition are thoroughly blended together, and the particles of crystalline benzoyl peroxide are simultaneously physically reduced in size, by milling the mixture to obtain a finished composition containing finely divided benzoyl peroxide pursuant to the practice of our invention.
The composition also contains from about 2 to by weight of at least one, and usually several, of certain organic emollients. Specifically, the organic emollient constituents of the composition should be selected from among those which are inert, and which are substantially non-ionic and non-polar, with respect to benzoyl peroxide and the other ingredients of the composition, and further from among those which have a boiling point higher than water. The term inert as employed herein refers to organic emollients which do not react chemically with benzoyl peroxide or with the other constituents of the composition at ambient temperature and pressure. In this connection, we have found that the presence of unsaturated carbon atoms in the emollient has an adverse effect on the stability and shelf life of the composition. Accordingly, the emollients preferably should be saturated organic compounds; that is, organic compounds that have no double or triple carbon to carbon atom bonds in the hydrocarbon chain. The terms non-ionic and non-polar as employed herein refer to emollient organic compounds which are insoluble in water at ordinary temperatures, or if soluble in water do not ionize therein to an appreciable degree. Finally, the requirement that the emollients have a boiling point higher than water is of importance to insure that some of the emollient will remain on the skin of the patient as a vehicle for the benzoyl peroxide after the evaporation of the Water content of the composition therefrom. Emollient compounds meeting these criteria include, but are not limited to, aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, fatty acids having from 12 to 20 carbon atoms, and the esters of said acids. Specific organic compounds representative of those useful in compositions of our invention include, but are not limited to, butyl alcohol, isobutyl alcohol, amyl alcohol, iso-amyl alcohol, hexyl alcohol, isohexyl alcohol, and the essentially water-insoluble higher aliphatic alcohols which are soluble in or softened by the aforementioned alcohols; ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol and the like; lauric acid, myristic acid, palmitic acid, stearic acid, and the like; and ethyl laurate, isopropyl laurate, ethyl myristate, n-propyl myristate, isopropyl myristate, ethyl palmitate, isopropyl palmitate, methyl palmitate, methyl stearate, ethyl stearate, isopropyl stearate, butyl stearate, isobutyl stearate, amyl stearate, isoamyl stearate, and the like.
In addition, the composition contains from about 50 to by weight water in which benzoyl peroxide is substantially insoluble. Advantageously, it also contains emulsifiers for the aqueous and non-aqueous phases of the composition, for example, polyethylene glycol 1000 monostearate, as well as preservatives such as methyl paraben (the methyl ester of parahydroxybenzoic acid) to prevent mold growth.
The composition also advantageously contains from about 1 to 25% by weight of finely divided sulfur, and preferably from about 2 to 10% by weight of precipitated sulfur, U.S.P. grade. Sulfur is an antimicrobial and keratolytic agent that has long been used in the treatment of acne. Although it is not known precisely how sulfur exerts its keratolytic effect on the skin, it is through that hydrogen sulfide, which is formed when sulfur is in contact with animal tissue, reacts with alkali in tissue fluids to produce active sulfides which, in turn, promote keratolysis. The combination of precipitated sulfur with benzoyl peroxide produces significantly greater keratolysis than either substance will when used alone. The mechanism responsible for this result is not known. However, it may be that the strong oxidizing properties of benzoyl peroxide facilitate the reaction between the active sulfides and keratin, or benzoyl peroxide may have some direct effect or keratin which makes it more susceptible to the action of the sulfide. In any case, the combination of benzoyl peroxide and sulfur in our new composition gives the composition properties which are especially useful in the treatment of acne.
The composition is prepared by carefully and thoroughtly blending the benzoyl peroxide, organic emollient, water and other constituents of the composition. Advantageously, the fluid medium in which the benzoyl peroxide is to be dispersed is first prepared by forming an emulsion of the aqueous and non-aqueous phases of the fluid medium. The benzoyl peroxide and sulfur, if any, constituents of the composition are then added to the emulsion and thoroughly blended therewith to form the therapeutic compostion of our invention. If the benzoyl peroxide constituent is in the form of dry, finely divided crystalline particles no further treatment of the composition is required, However, When the benzoyl peroxide is in the form of relatively coarse crystals packaged wet With water, the mixture of benzoyl peroxide and water is thoroughly mixed with a previously emulsified mixture of the emollient and water constituents of the composition, and the composition is then milled to physically reduce the particle size of the benzoyl peroxide crystals so that substantially all of the particles are smaller than 0.25 mm. in size.
The composition is applied topically to the skin of the patient by rubbing the cream or ointment in well,
once a day, and leaving it on the skin for about two hours after which it is removed by washing with water. If, after two days, treatment remains comfortable, the time of application is increased to four hours daily for four days. Thereafter, nightly applications usually suffice for maintenance as long as no irritation develops. usually at some time within the first four weeks of treatment, a dramatic and suddent generalized peeling or desquamation of the skin occurs in the treated areas. When this occurs, treatment is temporarily discontinued until the reaction subsides, and then application of the composition is resumed at the previous level of treatment.
Almost all persons who use our new composition for the treatment of acne show definite suppression of their eruption within the first few weeks of treatment. The
skin first becomes distinctly less oily, and then begins to desquamate. Individuals with minor to moderate papular and pustular acne show prompt suppression of their eruption and usually are well controlled within three months. Individuals with moderately severe acne show a prompt favorable response but require four to six months to obtain good control. Individuals with severe cystic acne, while slower to respond than those with non-cystic acne, obtain excellent suppression of their eruption within six to nine months in all but a few cases.
The following examples are representative but not limitative of therapeutic compositions prepared in accordance with our invention:
(I) Percent by weight Benzoyl peroxide 5.0 Stearic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 73.5
(II) Percent by weight Benzoyl peroxide 10.0 Palmitic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 68.5
(III) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 2.0 Stearic acid 6.2 Ethyl stearate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 71.5
(IV) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 10.0 Stearic acid 6.2 Isopropyl palmitate 3.8 Glyceryl monostearate 4.0 Polyethylene glycol 1000 monostearate 5.2 Ethylene glycol 2.2 Methyl paraben 0.1 Deionized water 63.5
. Percent by weight Benzoyl peroxide 5.0 2.0
Precipitated sulfur Myristic acid 1.6 Amyl stearate 1.0 Glyceryl monostearate 1.0
Polyethylene glycol 1000 monostearate 1.3 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 85.8
(VI) Percent by weight Benzoyl peroxide 5.0 Precipitated sulfur 10.0 Stearic acid 1.6 Isopropyl palmitate 1.0 Glyceryl laurate 1.0 Polyethylene glycol 1000 monostearate 1.3 Propylene glycol 2.2 Methyl paraben 0.1 Deionized water 77.8
(VII) Percent by weight Benzoyl peroxide 5.0 Stearic acid 1.9 Palmitic acid 1.2 Isopropyl palmitate 1.2 Glyceryl laurate 1.2 Polyethylene glycol 1000 monostearate 2.5 Propylene glycol 2.5 Methyl paraben 0.1 Deionized water 84.4
(VIII) Percent by wt. Benzoyl peroxide 20.0 Laurie acid 1.4 Isoamyl stearate 1.9 Glyceryl monostearate 1.9 Polyethylene glycol 1000 monostearate 1.2 Propylene glycol 2.0 Methyl paraben 0.1 Deionized water 71.5
(IX) Percent by wt. Benzoyl peroxide 10.0 Precipitated sulfur 10.0 Stearic acid 0.7 Isopropyl palmitate 0.45 Glyceryl monostearate 0.45 Polyethylene glycol 1000 monostearate 0.6 Diethylene glycol 1.0 Methyl paraben 0.1 Deionized water 76.7
(X) Percent by wt. Benzoyl peroxide 20.0 Precipitated sulfur 25.0 Lauryl alcohol 0.4 Isopropyl palmitate 0.3 Glyceryl monostearate 0.3 Polyethylene glycol 1000 monostearate 0.4 Propylene glycol 0.6 Methyl paraben 0.1 Deionized water 52.9
The most widely used composition of our invention contains 5% benzoyl peroxide and 2% sulfur. However, compositions containing 20% benzoyl peroxide and up to 25% sulfur have been used by individuals with dark, very oily skin and by those who have developed resistance to compositions of lesser strength, and compositions containing only 1.25% benzoyl peroxide and 0.5% sulfur have been used by individuals with fair and delicate skin. In all cases the compositions prepared in accordance with our invention are stable and retain full potency of the benzoyl peroxide constituent thereof for a period of time, i.e., for about eight years or more, which far exceeds the normal requirements for a pharmaceutical product.
From the foregoing description of our new composition for the treatment of acne it will be seen that we have made an important contribution to the art to which our invention relates.
We claim:
1. A therapeutic composition for the treatment of acne that is stable in storage Without the addition of a stabilizer thereto which consists of a uniform dispersion of finely divided particles of crystalline benzoyl peroxide in a fluid medium consisting essentially of water and an organic emollient selected from the group consisting of saturated aliphatic alcohols having from 4 to 20 carbon atoms, glycols having 2 to 3 carbon atoms, saturated fatty acids having from 12 to 20 carbon atoms, lower alkyl and glyceryl esters of said fatty acids having from 12 to 20 carbon atoms, and mixtures thereof, said organic emollient being inert, non-polar and non-ionic with respect to the other constituents of the composition and that have a boiling point higher than water, said composition containing from about 1 to 25% by weight benzoyl peroxide, from about 2 to 25% by weight of said organic emollient and from about 50 to 90% by weight water.
2. The therapeutic composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide.
3. The therapeutic composition according to claim 1 in which the composition contains from about 1 to 25% by weight finely divided sulfur.
4. The therapeutic composition according to claim 1 in which the composition contains from about 5 to 10% by weight benzoyl peroxide and from about 2 to 10% by weight finely divided sulfur.
References Cited UNITED STATES PATENTS 735,930 8/1962 Klaron.
FOREIGN PATENTS 793,471 11/ 1935 France.
821,726 10/1959 Great Britain.
OTHER REFERENCES ALBERT T. MEYERS, Primary Examiner D. R. ORE, Assistant Examiner US. Cl. X.R. 424-338
US711861A 1968-03-11 1968-03-11 Stable benzoyl peroxide composition Expired - Lifetime US3535422A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71186168A 1968-03-11 1968-03-11

Publications (1)

Publication Number Publication Date
US3535422A true US3535422A (en) 1970-10-20

Family

ID=24859841

Family Applications (1)

Application Number Title Priority Date Filing Date
US711861A Expired - Lifetime US3535422A (en) 1968-03-11 1968-03-11 Stable benzoyl peroxide composition

Country Status (1)

Country Link
US (1) US3535422A (en)

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2418386A1 (en) * 1973-04-16 1974-10-31 Stiefel Laboratories PRODUCTS FOR TREATMENT OF ACNE
US4075353A (en) * 1976-06-09 1978-02-21 Dermatologics For Veterinary Medicine, Inc. Process for the treatment of acarid skin infections in animals
US4129647A (en) * 1977-10-17 1978-12-12 Edmund Klein Treatment of acne
US4163800A (en) * 1977-08-17 1979-08-07 The Procter & Gamble Company Topical composition and treatment of skin lesions therewith
US4189501A (en) * 1977-10-07 1980-02-19 A. H. C. Pharmacal, Inc. Composition and method for the treatment of acne
EP0013459A2 (en) * 1979-01-08 1980-07-23 THE PROCTER & GAMBLE COMPANY Topical anti-acne compositions
US4228163A (en) * 1979-03-30 1980-10-14 Dermik Laboratories Method for treating pseudofolliculitis barbae
US4297348A (en) * 1980-04-11 1981-10-27 Rush-Hampton Industries, Inc. Composition and method for the treatment of acne
US4318907A (en) * 1978-04-04 1982-03-09 Westwood Pharmaceuticals, Inc. Method for treating acne vulgaris and compositions useful for that purpose
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4350681A (en) * 1977-10-07 1982-09-21 A.H.C. Pharmacal, Inc. Stabilized benzoyl peroxide compositions
US4355028A (en) * 1978-04-04 1982-10-19 Westwood Pharmaceuticals, Inc. Composition for treating acne vulgaris
US4361584A (en) * 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4364940A (en) * 1981-02-23 1982-12-21 Usv Pharmaceutical Corporation Compositions for treating acne
FR2517203A1 (en) * 1981-12-01 1983-06-03 Wolff Chem Pharm Gmbh COMPOSITION FOR THE TREATMENT OF ACNE
US4387107A (en) * 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4401835A (en) * 1981-09-17 1983-08-30 Warner-Lambert Company Method for preparing small sized benzoyl peroxide crystals
EP0129283A2 (en) * 1983-06-21 1984-12-27 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions containing corticosteroids
EP0129284A2 (en) 1983-06-21 1984-12-27 THE PROCTER & GAMBLE COMPANY Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4514384A (en) * 1983-03-14 1985-04-30 Gallina Damian J Hemorrhoid treatment method
US4518583A (en) * 1983-02-22 1985-05-21 Gallina Damian J Hemorrhoid and anorectal disease treatment method
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4540567A (en) * 1976-10-15 1985-09-10 Lever Brothers Company Cosmetic composition
US4545990A (en) * 1982-11-22 1985-10-08 L'oreal Anti-acne composition
EP0164716A2 (en) * 1984-06-11 1985-12-18 Richardson-Vicks, Inc. Stabilized clear benzoyl peroxide compositions
FR2604435A1 (en) * 1986-09-30 1988-04-01 Oreal UNSATURATED AROMATIC PEROXIDES AND THEIR USE IN THERAPEUTICS AND COSMETICS
US4900721A (en) * 1986-06-09 1990-02-13 Henkel Kommanditgesellschaft Auf Aktien Disinfectants and their use for disinfecting the skin and mucous membrane
EP0331489A3 (en) * 1988-03-03 1990-03-28 Parke Davis Pty. Ltd. Acne treatment
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5057479A (en) * 1990-05-09 1991-10-15 Witco Corporation Aqueous dispersions of aromatic diacyl peroxides
US5057500A (en) * 1990-02-12 1991-10-15 Dermatologic Research Corporation Treatment of pruritis with esters and amides
US5162280A (en) * 1988-01-27 1992-11-10 Witco Corporation Aqueous dispersions of aromatic diacyl peroxides
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
US5260390A (en) * 1980-01-16 1993-11-09 Akzo N.V. Peroxide emulsions containing an antifreezing compound
US5300600A (en) * 1989-10-12 1994-04-05 Witco Corporation Aqueous dispersions of peroxides
US5470884A (en) * 1994-05-19 1995-11-28 Procter & Gamble Anti-acne compositions
US5733886A (en) * 1992-02-18 1998-03-31 Lloyd J. Baroody Compositions of clindamycin and benzoyl peroxide for acne treatment
US5767098A (en) * 1985-12-12 1998-06-16 Dermik Laboratories, Inc. Anti-acne method and composition
US6013637A (en) * 1998-06-12 2000-01-11 Dermik Laboratories Inc. Anti-acne method and composition
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
US6462025B2 (en) 2000-12-12 2002-10-08 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20040132938A1 (en) * 2001-03-23 2004-07-08 O Boen Ho Storage stable aqueous organic peroxide emulsions
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US20050100585A1 (en) * 2003-07-03 2005-05-12 Patel Bhiku G. Delivery system for topical medications
US20060019935A1 (en) * 2004-07-20 2006-01-26 Watson Dana M Composition and method for treating acne including anti-inflammatory Hepes Oleate
US7060732B2 (en) 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US20080033031A1 (en) * 2004-11-19 2008-02-07 Aventis Pharmaceuticals Inc. Antibiotic compounds, compositions and methods of treatment
FR2910321A1 (en) * 2006-12-21 2008-06-27 Galderma Res & Dev S N C Snc Composition comprising a retinoid and benzoyl peroxide, e.g. for treating acne, is in the form of a gel cream
FR2910320A1 (en) * 2006-12-21 2008-06-27 Galderma Res & Dev S N C Snc Stable dermatological or cosmetic composition, useful e.g. for combating acne vulgaris or skin aging, comprises emulsion containing retinoid and benzoyl peroxide in dispersed form
US20080176954A1 (en) * 2001-12-21 2008-07-24 Galderma Research & Development, S.N.C. Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US20090234027A1 (en) * 2008-03-14 2009-09-17 Nathan Strick Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea
US20100099733A1 (en) * 2008-10-20 2010-04-22 Gordon Jay Dow Method for obtaining a stable dispersion of benzoyl peroxide
US20100143285A1 (en) * 2006-11-28 2010-06-10 Galderma Research & Development, Biot, France. Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer
US20110092562A1 (en) * 2009-10-21 2011-04-21 Gordon Jay Dow Method for wetting a powder containing benzoyl peroxide
WO2014076136A1 (en) * 2012-11-13 2014-05-22 Galderma S.A. Bpo wash emulsion composition
WO2016077818A1 (en) 2014-11-14 2016-05-19 Melinta Therapeutics, Inc. Method for treating, preventing, or reducing the risk of skin infection
WO2017200979A1 (en) 2016-05-17 2017-11-23 Melinta Therapeutics, Inc. Topical formulations of biaryl heterocyclic compounds and methods of use thereof
US10610594B2 (en) 2012-11-13 2020-04-07 Galderma S.A. BPO wash gel composition
US10688117B2 (en) 2011-05-27 2020-06-23 Galderma S.A. Topical wash composition for use in acne patients

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735930A (en) * 1902-09-18 1903-08-11 Chicago Motor Vehicle Company Engine-governor.
FR793471A (en) * 1934-08-01 1936-01-25 Autoxygen Improvement in the manufacturing process of a cosmetic composition
GB821726A (en) * 1956-03-06 1959-10-14 Pierre Francoise Isidore Josep Cosmetic product for skin treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US735930A (en) * 1902-09-18 1903-08-11 Chicago Motor Vehicle Company Engine-governor.
FR793471A (en) * 1934-08-01 1936-01-25 Autoxygen Improvement in the manufacturing process of a cosmetic composition
GB821726A (en) * 1956-03-06 1959-10-14 Pierre Francoise Isidore Josep Cosmetic product for skin treatment

Cited By (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056611A (en) * 1973-04-16 1977-11-01 Stiefel Laboratories, Inc. Therapeutic composition
DE2418386A1 (en) * 1973-04-16 1974-10-31 Stiefel Laboratories PRODUCTS FOR TREATMENT OF ACNE
US4075353A (en) * 1976-06-09 1978-02-21 Dermatologics For Veterinary Medicine, Inc. Process for the treatment of acarid skin infections in animals
US4540567A (en) * 1976-10-15 1985-09-10 Lever Brothers Company Cosmetic composition
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4163800A (en) * 1977-08-17 1979-08-07 The Procter & Gamble Company Topical composition and treatment of skin lesions therewith
US4350681A (en) * 1977-10-07 1982-09-21 A.H.C. Pharmacal, Inc. Stabilized benzoyl peroxide compositions
US4189501A (en) * 1977-10-07 1980-02-19 A. H. C. Pharmacal, Inc. Composition and method for the treatment of acne
US4361584A (en) * 1977-10-07 1982-11-30 A.H.C. Pharmacal, Inc. Composition and method for the treatment of acne
US4129647A (en) * 1977-10-17 1978-12-12 Edmund Klein Treatment of acne
US4355028A (en) * 1978-04-04 1982-10-19 Westwood Pharmaceuticals, Inc. Composition for treating acne vulgaris
US4318907A (en) * 1978-04-04 1982-03-09 Westwood Pharmaceuticals, Inc. Method for treating acne vulgaris and compositions useful for that purpose
EP0013459A2 (en) * 1979-01-08 1980-07-23 THE PROCTER & GAMBLE COMPANY Topical anti-acne compositions
US4954487A (en) * 1979-01-08 1990-09-04 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
EP0013459A3 (en) * 1979-01-08 1981-05-13 THE PROCTER & GAMBLE COMPANY Topical anti-acne compositions
US4228163A (en) * 1979-03-30 1980-10-14 Dermik Laboratories Method for treating pseudofolliculitis barbae
US4387107A (en) * 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US5369197A (en) * 1980-01-16 1994-11-29 Akzo N.V. Peroxide emulsions containing an antifreezing compound
US5260390A (en) * 1980-01-16 1993-11-09 Akzo N.V. Peroxide emulsions containing an antifreezing compound
US4297348A (en) * 1980-04-11 1981-10-27 Rush-Hampton Industries, Inc. Composition and method for the treatment of acne
US4364940A (en) * 1981-02-23 1982-12-21 Usv Pharmaceutical Corporation Compositions for treating acne
US4401835A (en) * 1981-09-17 1983-08-30 Warner-Lambert Company Method for preparing small sized benzoyl peroxide crystals
FR2517203A1 (en) * 1981-12-01 1983-06-03 Wolff Chem Pharm Gmbh COMPOSITION FOR THE TREATMENT OF ACNE
US4545990A (en) * 1982-11-22 1985-10-08 L'oreal Anti-acne composition
US4518583A (en) * 1983-02-22 1985-05-21 Gallina Damian J Hemorrhoid and anorectal disease treatment method
US4514384A (en) * 1983-03-14 1985-04-30 Gallina Damian J Hemorrhoid treatment method
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
EP0129283A2 (en) * 1983-06-21 1984-12-27 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions containing corticosteroids
EP0129284A2 (en) 1983-06-21 1984-12-27 THE PROCTER & GAMBLE COMPANY Improved penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4557934A (en) * 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4537776A (en) * 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
EP0129283A3 (en) * 1983-06-21 1987-11-11 The Procter & Gamble Company Improved penetrating topical pharmaceutical compositions containing corticosteroids
US4609674A (en) * 1984-06-11 1986-09-02 Richardson-Vicks Inc. Stabilized clear benzoyl peroxide compositions
EP0164716A3 (en) * 1984-06-11 1986-08-20 Richardson-Vicks, Inc. Stabilized clear benzoyl peroxide compositions
EP0164716A2 (en) * 1984-06-11 1985-12-18 Richardson-Vicks, Inc. Stabilized clear benzoyl peroxide compositions
US5767098A (en) * 1985-12-12 1998-06-16 Dermik Laboratories, Inc. Anti-acne method and composition
US4900721A (en) * 1986-06-09 1990-02-13 Henkel Kommanditgesellschaft Auf Aktien Disinfectants and their use for disinfecting the skin and mucous membrane
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
FR2604435A1 (en) * 1986-09-30 1988-04-01 Oreal UNSATURATED AROMATIC PEROXIDES AND THEIR USE IN THERAPEUTICS AND COSMETICS
US4803228A (en) * 1986-09-30 1989-02-07 L'oreal Unsaturated aromatic peroxides and their use in pharmaceutical and cosmetic compositions
BE1004154A4 (en) * 1986-09-30 1992-10-06 Oreal Aromatic unsaturated peroxides and therapeutic use and cosmetics.
US5162280A (en) * 1988-01-27 1992-11-10 Witco Corporation Aqueous dispersions of aromatic diacyl peroxides
EP0331489A3 (en) * 1988-03-03 1990-03-28 Parke Davis Pty. Ltd. Acne treatment
AU619256B2 (en) * 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
US5300600A (en) * 1989-10-12 1994-04-05 Witco Corporation Aqueous dispersions of peroxides
US5057500A (en) * 1990-02-12 1991-10-15 Dermatologic Research Corporation Treatment of pruritis with esters and amides
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5057479A (en) * 1990-05-09 1991-10-15 Witco Corporation Aqueous dispersions of aromatic diacyl peroxides
US5733886A (en) * 1992-02-18 1998-03-31 Lloyd J. Baroody Compositions of clindamycin and benzoyl peroxide for acne treatment
US5470884A (en) * 1994-05-19 1995-11-28 Procter & Gamble Anti-acne compositions
US6013637A (en) * 1998-06-12 2000-01-11 Dermik Laboratories Inc. Anti-acne method and composition
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
US6774100B2 (en) 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
US20060173076A1 (en) * 2000-12-12 2006-08-03 Mohan Vishnupad Antibiotic/benzoyl peroxide dispenser
US6462025B2 (en) 2000-12-12 2002-10-08 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US7060732B2 (en) 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060172955A1 (en) * 2000-12-12 2006-08-03 Mohan Vishnupad Antibiotic/benzoyl peroxide dispenser
US20040132938A1 (en) * 2001-03-23 2004-07-08 O Boen Ho Storage stable aqueous organic peroxide emulsions
US7214329B2 (en) * 2001-03-23 2007-05-08 Akzo Nobel N.V. Storage stable aqueous organic peroxide emulsions
US8936800B2 (en) 2001-12-21 2015-01-20 Galderma Research & Development Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
US9814690B2 (en) 2001-12-21 2017-11-14 Galderma Research & Development Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
US20110070274A1 (en) * 2001-12-21 2011-03-24 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US20080176954A1 (en) * 2001-12-21 2008-07-24 Galderma Research & Development, S.N.C. Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide
US8241649B2 (en) 2001-12-21 2012-08-14 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
US8105618B2 (en) 2001-12-21 2012-01-31 Galderma Research & Development Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US20110313051A1 (en) * 2003-07-03 2011-12-22 Patel Bhiku G Delivery system for topical medications
US20050100585A1 (en) * 2003-07-03 2005-05-12 Patel Bhiku G. Delivery system for topical medications
US20070110794A1 (en) * 2003-07-03 2007-05-17 Patel Bhiku G Delivery system for topical medications
US20060019935A1 (en) * 2004-07-20 2006-01-26 Watson Dana M Composition and method for treating acne including anti-inflammatory Hepes Oleate
US20080033031A1 (en) * 2004-11-19 2008-02-07 Aventis Pharmaceuticals Inc. Antibiotic compounds, compositions and methods of treatment
US8568704B2 (en) * 2006-11-28 2013-10-29 Galderma Research & Development Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer
US20100143285A1 (en) * 2006-11-28 2010-06-10 Galderma Research & Development, Biot, France. Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer
CN101631594A (en) * 2006-12-21 2010-01-20 盖尔德马研究及发展公司 Emulsion comprising at least one retinoid and benzoyl peroxide
FR2910320A1 (en) * 2006-12-21 2008-06-27 Galderma Res & Dev S N C Snc Stable dermatological or cosmetic composition, useful e.g. for combating acne vulgaris or skin aging, comprises emulsion containing retinoid and benzoyl peroxide in dispersed form
US20090318550A1 (en) * 2006-12-21 2009-12-24 Galderma Research & Development Emulsions comprising at least one retinoid and benzoyl peroxide
US20100166852A1 (en) * 2006-12-21 2010-07-01 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
US10925814B2 (en) 2006-12-21 2021-02-23 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
US10702466B2 (en) 2006-12-21 2020-07-07 Galderma Research & Development Emulsions comprising at least one retinoid and benzoyl peroxide
WO2008087354A3 (en) * 2006-12-21 2008-11-13 Galderma Res & Dev Cream-gel comprising at least one retinoid and benzoyl peroxide
WO2008087348A3 (en) * 2006-12-21 2008-11-06 Galderma Res & Dev Emulsion comprising at least one retinoid and benzoyl peroxide
EP2460561A1 (en) * 2006-12-21 2012-06-06 Galderma Research & Development Emulsion comprising at least one retinoid and benzoyl peroxide
EP2460562A1 (en) * 2006-12-21 2012-06-06 Galderma Research & Development Cream-gel comprising at least one retinoid and benzoyl peroxide
WO2008087354A2 (en) * 2006-12-21 2008-07-24 Galderma Research & Development Cream-gel comprising at least one retinoid and benzoyl peroxide
WO2008087348A2 (en) * 2006-12-21 2008-07-24 Galderma Research & Development Emulsion comprising at least one retinoid and benzoyl peroxide
US9999577B2 (en) * 2006-12-21 2018-06-19 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
FR2910321A1 (en) * 2006-12-21 2008-06-27 Galderma Res & Dev S N C Snc Composition comprising a retinoid and benzoyl peroxide, e.g. for treating acne, is in the form of a gel cream
US8957112B2 (en) 2006-12-21 2015-02-17 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
US20150098918A1 (en) * 2006-12-21 2015-04-09 Galderma Research & Development Cream gels comprising at least one retinoid and benzoyl peroxide
EP3025763A1 (en) * 2006-12-21 2016-06-01 Galderma Research & Development Cream gel comprising at least one retinoid and benzoyl peroxide
US20090234027A1 (en) * 2008-03-14 2009-09-17 Nathan Strick Topical gel cosmetic formulation of cellacefate for the control of acne and rosacea
US20100099733A1 (en) * 2008-10-20 2010-04-22 Gordon Jay Dow Method for obtaining a stable dispersion of benzoyl peroxide
US9744150B2 (en) * 2009-10-21 2017-08-29 Dow Pharmaceutical Sciences Inc. Suspension containing micronized benzoyl peroxide
US20110092562A1 (en) * 2009-10-21 2011-04-21 Gordon Jay Dow Method for wetting a powder containing benzoyl peroxide
US10688117B2 (en) 2011-05-27 2020-06-23 Galderma S.A. Topical wash composition for use in acne patients
WO2014076136A1 (en) * 2012-11-13 2014-05-22 Galderma S.A. Bpo wash emulsion composition
US10610594B2 (en) 2012-11-13 2020-04-07 Galderma S.A. BPO wash gel composition
US11446272B2 (en) 2012-11-13 2022-09-20 Galderma Holding SA BPO wash emulsion composition
WO2016077818A1 (en) 2014-11-14 2016-05-19 Melinta Therapeutics, Inc. Method for treating, preventing, or reducing the risk of skin infection
US10471046B2 (en) 2014-11-14 2019-11-12 Melinta Subsidary Corp. Method for treating, preventing, or reducing the risk of skin infection
WO2017200979A1 (en) 2016-05-17 2017-11-23 Melinta Therapeutics, Inc. Topical formulations of biaryl heterocyclic compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
US3535422A (en) Stable benzoyl peroxide composition
US4056611A (en) Therapeutic composition
US4387107A (en) Stable benzoyl peroxide composition
US4545990A (en) Anti-acne composition
US3906108A (en) Stabilized tretinoin cream emulsion
US4923900A (en) Therapeutic compositions containing benzoyl peroxide
US5397497A (en) Bath additive composition containing polyglycerol fatty acid ester mixture
US6433024B1 (en) Topical anti-acne composition
US5503825A (en) Lip balm composition
US5086075A (en) Therapeutic compositions containing benzoyl peroxide
US4178373A (en) Coal tar gel composition
US4593046A (en) Method of reducing skin irritation from benzoyl peroxide
JPS60142920A (en) Anti-acne agent
PT94485A (en) METHOD FOR PREPARING A STABLE, COSMETICALLY ACCEPTABLE TOPIC GEL FORMULA, CONTAINING A TETRACYCLINE, USEFUL IN ACNE TREATMENT
EP0831768A1 (en) Topical vehicles containing solubilized and stabilized azelaic acid
JPH0215022A (en) Anti-imflammatory skin wetting composition and preparation thereof
HUT53518A (en) Process for producing skin moistening pharmaceutical composition comprising vitamins a as active ingredient
US6210693B1 (en) Oil-in-water type emulsified composition
JPS5883648A (en) Lanolin acid copper and local composition
CA1156558A (en) Stable benzoyl peroxide composition
US4062937A (en) Insect bite relief preparation
EP0304802A2 (en) Pharmaceutical composition and the use thereof
US5728690A (en) Clear non-alcoholic hydrocortisone solutions
CA1099636A (en) Dithranol composition for the treatment of psoriasis
US20100010091A1 (en) Anhydrous, Dermatological or Cosmetic Preparation Containing Urea